

Kyoung Hyun Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5860582/publications.pdf>

Version: 2024-02-01

31
papers

3,605
citations

304743

22
h-index

414414

32
g-index

32
all docs

32
docs citations

32
times ranked

6307
citing authors

#	ARTICLE	IF	CITATIONS
1	The androgen receptor inhibits transcription of GPER1 by preventing Sp1 and Sp3 from binding to the promoters in prostate cancer cells. <i>Oncotarget</i> , 2022, 13, 46-60.	1.8	3
2	Regulation of a long noncoding RNA MALAT1 by aryl hydrocarbon receptor in pancreatic cancer cells and tissues. <i>Biochemical and Biophysical Research Communications</i> , 2020, 532, 563-569.	2.1	14
3	NR2E3 is a key component in p53 activation by regulating a long noncoding RNA DINO in acute liver injuries. <i>FASEB Journal</i> , 2019, 33, 8335-8348.	0.5	14
4	Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer. <i>Scientific Reports</i> , 2017, 7, 10662.	3.3	17
5	Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells. <i>Oncotarget</i> , 2016, 7, 22245-22256.	1.8	85
6	Deregulation of NR2E3, an orphan nuclear receptor, by benzo(a)pyrene-induced oxidative stress is associated with histone modification status change of the estrogen receptor gene promoter. <i>Toxicology Letters</i> , 2015, 237, 228-236.	0.8	13
7	Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC. <i>Oncotarget</i> , 2015, 6, 26359-26372.	1.8	27
8	Mechanism of Action of Phenethylisothiocyanate and Other Reactive Oxygen Species-Inducing Anticancer Agents. <i>Molecular and Cellular Biology</i> , 2014, 34, 2382-2395.	2.3	100
9	Herbal Medicines for Inflammatory Diseases. <i>Mediators of Inflammation</i> , 2014, 2014, 1-1.	3.0	5
10	The Transcriptional Repressor ZBTB4 Regulates EZH2 Through a MicroRNA-ZBTB4-Specificity Protein Signaling Axis. <i>Neoplasia</i> , 2014, 16, 1059-1069.	5.3	36
11	MicroRNA-26b Represses Colon Cancer Cell Proliferation by Inhibiting Lymphoid Enhancer Factor 1 Expression. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1942-1951.	4.1	33
12	Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. <i>International Journal of Cancer</i> , 2013, 132, 795-806.	5.1	35
13	Aryl Hydrocarbon Receptor Agonists Induce MicroRNA-335 Expression and Inhibit Lung Metastasis of Estrogen Receptor Negative Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 108-118.	4.1	85
14	Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1852-1862.	4.1	50
15	Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1421-1431.	4.1	79
16	FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. <i>Carcinogenesis</i> , 2012, 33, 1843-1853.	2.8	103
17	Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. <i>EMBO Molecular Medicine</i> , 2012, 4, 52-67.	6.9	42
18	Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer. <i>PLoS ONE</i> , 2011, 6, e24662.	2.5	105

#	ARTICLE	IF	CITATIONS
19	Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors. <i>Carcinogenesis</i> , 2011, 32, 836-842.	2.8	70
20	Mdm2 Regulates Estrogen Receptor $\hat{\alpha}$ and Estrogen-responsiveness in Breast Cancer Cells. <i>Journal of Molecular Endocrinology</i> , 2010, 46, 67-79.	2.5	20
21	MicroRNA-27a Indirectly Regulates Estrogen Receptor $\hat{\pm}$ Expression and Hormone Responsiveness in MCF-7 Breast Cancer Cells. <i>Endocrinology</i> , 2010, 151, 2462-2473.	2.8	88
22	Inactivation of the Orphan Nuclear Receptor TR3/Nur77 Inhibits Pancreatic Cancer Cell and Tumor Growth. <i>Cancer Research</i> , 2010, 70, 6824-6836.	0.9	139
23	Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. <i>Journal of Molecular Endocrinology</i> , 2008, 41, 263-275.	2.5	278
24	In Vivo Profiling of Estrogen Receptor/Specificity Protein-Dependent Transactivation. <i>Endocrinology</i> , 2008, 149, 5696-5705.	2.8	13
25	Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production. <i>Science</i> , 2007, 317, 121-124.	12.6	1,665
26	Molecular Mechanism of Inhibitory Aryl Hydrocarbon Receptor $\hat{\alpha}$ Estrogen Receptor/Sp1 Cross Talk in Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2006, 20, 2199-2214.	3.7	57
27	3-Methylcholanthrene and Other Aryl Hydrocarbon Receptor Agonists Directly Activate Estrogen Receptor $\hat{\pm}$. <i>Cancer Research</i> , 2006, 66, 2459-2467.	0.9	120
28	DRIP150 Coactivation of Estrogen Receptor $\hat{\pm}$ in ZR-75 Breast Cancer Cells Is Independent of LXXLL Motifs. <i>Journal of Biological Chemistry</i> , 2005, 280, 8819-8830.	3.4	19
29	Analysis of Estrogen Receptor $\hat{\pm}$ -Sp1 Interactions in Breast Cancer Cells by Fluorescence Resonance Energy Transfer. <i>Molecular Endocrinology</i> , 2005, 19, 843-854.	3.7	58
30	Nuclear Receptor-Mediated Transactivation Through Interaction with Sp Proteins. <i>Progress in Molecular Biology and Translational Science</i> , 2004, 77, 1-36.	1.9	128
31	Domains of Estrogen Receptor $\hat{\pm}$ (ER $\hat{\pm}$) Required for ER $\hat{\pm}$ /Sp1-Mediated Activation of GC-Rich Promoters by Estrogens and Antiestrogens in Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2003, 17, 804-817.	3.7	103